Clinical features of patients with sinusoidal obstruction syndrome (SOS) following cyclophosphamide (CY)–based myeloablative regimens for hematopoietic cell transplantation.*
| . | Mild . | Moderate . | Severe . |
|---|---|---|---|
| * The data are observations through day 20 post-transplant, according to severity of disease, expressed as the mean and standard deviation. | |||
| Reprinted with permission from the Annals of Internal Medicine 1993 ;118 :255 –267. | |||
| Weight gain (% increase) | 7.0 ± 3.5 % | 10.1 ± 5.3% | 15.5 ± 9.2% |
| Maximum bilirubin (mg/dL) | 4.7 ± 2.9 | 7.9 ± 6.6 | 26.0 ± 15.2 |
| Percentage with peripheral edema | 23% | 70% | 85% |
| Percentage with ascites | 5% | 16% | 48% |
| Day 100 mortality (all causes) | 3% | 20% | 98% |
| . | Mild . | Moderate . | Severe . |
|---|---|---|---|
| * The data are observations through day 20 post-transplant, according to severity of disease, expressed as the mean and standard deviation. | |||
| Reprinted with permission from the Annals of Internal Medicine 1993 ;118 :255 –267. | |||
| Weight gain (% increase) | 7.0 ± 3.5 % | 10.1 ± 5.3% | 15.5 ± 9.2% |
| Maximum bilirubin (mg/dL) | 4.7 ± 2.9 | 7.9 ± 6.6 | 26.0 ± 15.2 |
| Percentage with peripheral edema | 23% | 70% | 85% |
| Percentage with ascites | 5% | 16% | 48% |
| Day 100 mortality (all causes) | 3% | 20% | 98% |